Biener, Leonie and Muemmler, Carlo and Hinze, Christopher Alexander and Suhling, Hendrik and Korn, Stephanie and Fisser, Christoph and Biener, Arne and Pizarro, Carmen and Lenoir, Alexandra and Hackl, Caroline and Skowasch, Dirk and Milger, Katrin (2024) Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 12 (9). 2399-2407.e5. ISSN 2213-2198, 2213-2201
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: Tezepelumab is a novel biologic blocking thymic stromal lymphopoetin, approved for severe asthma irrespective of biomarker levels or phenotype. OBJECTIVE: To characterize a real-world tezepelumab patient cohort and the efficacy among various asthma phenotypes. METHODS: We performed a retrospective, multicenter study on patients with severe asthma initiating tezepelumab. Clinical response was evaluated at 3 and 6 months. RESULTS: We included 129 patients with an average age of 52.5 - 13.1 years, 59.7% were female. The majority (86.0%) had increased type 2 (T2) biomarkers, 68.2% an allergic and 31.8% an eosinophilic phenotype. 23.3% of patients were biologic- naive. 22 (18.2%) patients discontinued tezepelumab therapy owing to suspected side effects or insufficient efficacy. At 6 months' follow-up, median reduction in annualized exacerbation rate was-1 [25th percentile; 75% percentile {-2.9; 0.0}], the reduction of oral corticosteroid dose among patients with longterm oral corticosteroid therapy was-5 mg [-10; 0] and the Asthma Control Test (ACT) improved by 2 [0; 5] points. A treatment response according to Biologic Asthma Response Score of 80.8% was demonstrated. There were no significant differences in treatment response between T2-high versus T2 low, early- versus adult-onset and eosinophilic versus noneosinophilic asthma. Prior treatment with other biologics was associated with inferior treatment response. CONCLUSIONS: In this real-life cohort, including a large proportion of patients with history of previous biologic use and encompassing various subgroups, the majority responded to tezepelumab. Our data further suggest a steroid-sparing effect of tezepelumab. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY- NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/). (J Allergy Clin Immunol Pract 2024;12:2399-407)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ADULTS; Severe asthma; Biologic; Antibody; Tezepelumab; Real-world; Switching |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Jan 2026 10:12 |
| Last Modified: | 22 Jan 2026 10:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65162 |
Actions (login required)
 |
View Item |
